Protalix Wins FDA Approval for Its First Drug on the Market
This article is for subscribers only.
Protalix BioTherapeutics Inc. jumped as much as 27 percent in extended trading after the drugmaker won approval for its debut medicine, a treatment it developed with Pfizer Inc. for a rare genetic disorder.
The Food and Drug Administration cleared the product called Elelyso to treat a condition caused by lack of an enzyme that can lead to spleen and liver enlargement known as Gaucher disease. The drug, chemically known as taliglucerase, is approved for Type 1 Gaucher disease affecting about 6,000 people in the U.S., the agency said in a statement today.